Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases

Blood

Volumn 105, Issue 11, 2005, Pages 4508-4515

  Xu, Mingjiang ^b   Bruno, Edward ^b   Chao, Joseph ^b   Huang, Stephen ^b   Finazzi, Guido ^b   Fruchtman, Steven M ^b   Popat, Uday ^b   Prchal, Josef T ^b   Barosi, Giovanni ^b   Hoffman, Ronald ^a  

^a M C 700   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; LEUKOCYTE ELASTASE; STEM CELL FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BASEMENT MEMBRANE; BLOOD; BLOOD LEVEL; CD34 SELECTION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; MONONUCLEAR CELL; MYELOID METAPLASIA; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 21144457074     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3238     Document Type: Article

References (51)

1. Hoffman R, Ravandi F. Idiopathic myelofibrosis. In: Hoffman R, Benz E Jr, Shattil S, et al. Hematology: Basic Principles and Practice. 4th ed. New York, NY: Churchill Livingstone; 2004:1255-1276.
2. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
3. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-2970.
4. Thiele J, Pierre R, Imbert M, Vardiman JW, Brunning RD, Glandrin G. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris N, Stan N, Vardiman JW. World Health Organization of Tumors of Hematopoietic and Lymphoid Tissues. Washington DC: IARC Press; 2001:35-38.
5. + cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249-3255.
6. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002;30:973-981.
7. Papayannopoulou T. Bone marrow homing: the players, the playfield, and their evolving roles. Curr Opin Hematol. 2003;10:214-219.
8. Abkowitz JL, Robinson AE, Kale S, Long MW, Chen J. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood. 2003;102:1249-1253.
9. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3:687-694.
10. Prosper F, Stroncek D, Verfaillie CM. Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor. Blood. 1996;88:2033-2042.
11. + haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. Br J Haematol. 2000;110:71-81.
12. Carstanjen D, Ulbricht N, Iacone A, Regenfus M, Salama A. Matrix metalloproteinase-9 (gelatinase B) is elevated during mobilization of peripheral blood progenitor cells by G-CSF. Transfusion. 2002;42:588-596.
13. Lévesque J-P, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood. 2001;98:1289-1297.
14. Pruijt JF, Fibbe WE, Laterveer L, et al. Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci U S A. 1999;96:10863-10868.
15. Lévesque JP, Hendy J, Takamatsu Y, Williams B, Winkler IG, Simmons PJ. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol. 2002;30:440-449.
16. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625-637.
17. + cells and their transmigration through reconstituted basement membrane. Blood. 1999;93:3379-3390.
18. Lévesque JP, Hendy J, Winkler IG, Takamatsu Y, Simmons PJ. Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Exp Hematol. 2003;31:109-117.
19. Papayannopoulou T, Priestley GV, Nakamoto B. Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood. 1998;91:2231-2239.
20. Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood. 1998;91:100-110.
21. Delgado MB, Clark-Lewis I, Loetscher P, et al. Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes. Eur J Immunol. 2001;31:699-707.
22. + cells on vascular endothelium under shear flow. J Clin Invest. 1999;104:1199-1211.
23. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem. 2001;276:43503-43508.
24. + cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood. 2000;95:3289-3296.
25. Roland J, Murphy BJ, Ahr B, et al. Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. Blood. 2003;101:399-406.
26. Lane WJ, Dias S, Hattori K, et al. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood. 2000;96:4152-4159.
27. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 2003;111:187-196.
28. Pruijt JF, Verzaal P, van Os R, et al. Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice. Proc Natl Acad Sci U S A. 2002;99:6228-6233.
29. Levesque JP, Liu F, Simmons PJ, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood. 2004;104:65-72.
30. Hoffman R, Baker KR, Prchal JT. The polycythemias. n: Hoffman R, Benz E Jr, Shattil S, et al. Hematology: Basic Principles and Practice. 4th ed. New York, NY: Churchill Livingstone; 2004: 1209-1245.
31. Cheng M, De B, Pikul S, et al. Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. J Med Chem. 2000;43:369-380.
32. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J Immunol. 2001;167:5150-5259.
33. Carion A, Benboubker L, Herault O, et al. Stromal-derived factor 1 and matrix metalloproteinase 9 levels in bone marrow and peripheral blood of patients mobilized by granulocyte colony-stimulating factor and chemotherapy. Relationship with mobilizing capacity of haematopoietic progenitor cells. Br J Haematol. 2003;122:918-926.
34. + cells from normal human bone marrow, cord blood, peripheral blood, and mobilized peripheral blood from patients undergoing autologous stem cell transplantation. Clin Immunol Immunopathol. 1994;70:10-18.
35. Carella AM, Dejana A, Lerma E, et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol. 1996;95:127-130.
36. Saitoh H, Shibata A. Serum G-CSF levels in primary myelofibrosis and chronic neutrophilic leukemia as estimated by the highly sensitive chemiluminescence enzyme immunoassay (CLEIA). Leuk Lymphoma. 1996;22:515-517.
37. Poulsen LW, Melsen F, Bendix K. A histomorphometric study of haematological disorders with respect to marrow fibrosis and osteosclerosis. APMIS. 1998;106:495-499.
38. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99:2255-2258.
39. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912-3918.
40. Daly A, Song K, Nevill T, et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant. 2003;32:35-40.
41. Anderson JE, Tefferi A, Craig F, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood. 2001;98:586-593.
42. Centurione L, Di Baldassarre A, Zingariello M, et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood. 2004;104:3573-3580.
43. Sudhoff T, Sohngen D. Circulating endothelial adhesion molecules (sE-selectin, sVCAM-1 and sICAM-1) during rHuG-CSF-stimulated stem cell mobilization. J Hematother Stem Cell Res. 2002;11:147-151.
44. Dosquet C, Chen Y, Makke J, et al. Cytokines and vascular cell adhesion molecule-1 in the blood of patients undergoing HPC mobilization. Transfusion. 2001;41:206-212.
45. Xu M, Bruno E, Chao J, et al. The constitutive mobilization of bone marrow repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood. 2005;105:1699-1705.
46. + cells. Blood. 1994;84:2930-2939.
47. Long MW, Briddell R, Walter AW, Bruno E, Hoffman R. Human hematopoietic stem cell adherence to cytokines and matrix molecules. J Clin Invest. 1992;90:251-255.
48. Ries C, Loher F, Zang C, Ismair MG, Petrides PE. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Research. 1999;5:1115-1124.
49. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387-2392.
50. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets. 2003;7:385-397.
51. Purcell WT, Rudek MA, Hidalgo M. Development of matrix metalloproteinase inhibitors in cancer therapy. Hematol Oncol Clin N Am. 2002;16:1189-1227.